-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 13, Shanghai Pharmaceuticals issued an announcement stating that the caffeine citrate injection of its subsidiary, Shanghai Hefeng, received the "Drug Registration Certificate" issued by the State Drug Administration, and the drug was approved for production
.
Caffeine citrate injection is mainly used to treat primary apnea in premature newborns
.
It was first developed by Chies Pharmaceuticals and listed in the European Union in 2009
As of the date of this announcement, the main manufacturers of the drug in China are AlfasigmaS.
According to the IQVIA database, the purchase amount of the drug hospital in 2020 is RMB 174.
According to relevant national policies, the types of generic drugs approved under the new registration classification will receive greater support in areas such as medical insurance payment and procurement by medical institutions
